Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
The MarketWatch News Department was not involved in the creation of this content. Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau ...
Hosted on MSN
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
Brian Lian, President and CEO, highlighted several milestones in 2025, focusing on the obesity pipeline: "With the subcutaneous formulation of our lead molecule, VK2735, following the positive ...
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, ...
(RTTNews) - Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported its fourth-quarter and full-year 2025 financial results ...
SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results